FDA Brief

Warning letters Drugs

FDA warning letter to

Absara Cosmetics S.A.P.I DE C.V.

High riskIssued Feb 18, 2021Posted Feb 23, 2021Center for Drug Evaluation and Research | CDER

Absara Cosmetics' hand sanitizer labeled 70% ethanol tested at 58%, leading to CGMP citations.

What happened

FDA detained and refused admission of the hand sanitizer at the U.S. border and laboratory-tested a batch. Testing found 58% v/v ethanol although the label said 70%. After an Oct. 16, 2020 teleconference, FDA said the firm's test methods and investigation were inadequate, and FDA placed all firm drugs on Import Alert 66-78 on Feb. 4, 2021.

What FDA found

  1. The hand sanitizer labeled to contain 70% ethanol actually contained 58% v/v ethanol, so its strength was below its label.

    FD&C Act section 501(c), 21 U.S.C. 351(c)
  2. FDA said the lower strength shows that quality assurance at the facility is not working under CGMP.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The firm's test methods differed from USP methods without justification and lacked validation or equivalence documentation, an internal standard, system suitability, and had calculation errors.

    21 CFR 211.160
  4. The firm's investigation into the subpotent batch was not adequately justified, did not establish the root cause, and did not review test methods, laboratory operations, or analytical results.

    21 CFR 211.192

What FDA wants

FDA asks for a detailed follow-up investigation of the subpotency, a list of raw materials and suppliers, a reconciliation of all hand sanitizer batches shipped to the U.S., complete batch records, and the test methods and specifications used. The firm must respond in writing within 15 working days.

Who should pay attention

  • U.S. distributors and retailers of imported hand sanitizer
  • brands using Absara Cosmetics as a contract manufacturer
  • quality teams managing supplier verification for OTC drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  2. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  3. Shuzy Rock Inc.

    FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.

    High risk
  4. Guangzhou Zhongkebaishi Health Industry Co., Ltd.

    Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.

    High risk